ANZCTR search results

The aim of this study is to evaluate the impact of Smart-HF (a mHealth platform) on reducing readmission to hospital and other secondary outcomes. The Smart-HF platform is an app for the patient that delivers educational information, goal-setting, homework tasks, self-monitoring and questionnaires to patients with heart failure, and allows patient progress and outcomes to be measured via a clinician portal. Participants are patients admitted to the general or cardiology wards with Acute Decompensated Heart Failure (ADHF). Enrolled patients classified with a high risk of hospital readmission and/or death - i.e., equal to or greater than median of predicted risk, 33% based on the TAS-Help study algorithm developed by CIs Marwick and Huynh - will be randomised to either usual care or Smart-HF plus usual care, with stratification by study site and type of HF (reduced or preserved ejection fraction). The primary endpoint is quality of life at 90 days post hospital discharge. Secondary endpoints - 30-day readmission, 30- and 90-day composite outcome.

High and variable rates of psychotropic medication use persist in residential aged care facilities (RACFs) despite minimal evidence of benefit and increasing evidence of harm. Knowledge brokers are individuals or groups who facilitate the transfer of knowledge into practice. This study will employ an onsite pharmacist to act as a knowledge broker to implement new Clinical Practice Guidelines for the Appropriate Use of Psychotropic Medications in People Living with Dementia and in Residential Aged Care (the Guideline). The intervention will involve the delivery of three implementation strategies: Level 1 - passive distribution of the Guideline; Level 2 - current best practice; Level 3 - employment of a knowledge broker. Each RACF will receive each strategy for one of three psychotropics medication (antipsychotics, benzodiazepines and antidepressants). In the level 3 strategy, the knowledge broker will develop an action plan and will undertake a variety of ongoing local activities to facilitate implementation of the Guideline. It is hypothesised that the level 3 intervention knowledge broker will lead to improvements in Guideline concordant use of antipsychotics, benzodiazepines and antidepressants in RACFs compared to the other two levels.

ESCAPE-CS is the implementation of an evidence-based, best-practice Cardiogenic Shock care pathway that is hypothesised to improve mortality, safety, healthcare utilisation and QoL outcomes, and reduce inequity in access to care. It is a multicentre, two-phase prospective cohort study. Phase 1, a 12-month data collection of ‘usual care’ phase, is followed by Phase 2, a 12-month study intervention phase. The study intervention has three components: a streamlined referral system, a multidisciplinary shock team, and protocol-driven care. The study will be conducted in 7 participating centres across local health districts in NSW. These centres encompass a range of urban tertiary and non-tertiary, regional and rural sites, and have existing referral relationships with either a quaternary centre or another participating centre in the study.

The research project is an investigator-initiated, open-label, randomised controlled trial which will explore the effect of an educational intervention in enhancing the confidence and competence of nursing staff when caring for patients with Haemophilia. The intervention group will receive an educational intervention which will be a PowerPoint presentation. The control group will receive no intervention. The educational intervention is a 30-60 minute PowerPoint presentation. A link to the recording of the Microsoft Teams presentation will be emailed to participants. The presentation will contain information, graphics, and visual aids relevant to Haemophilia and best-practice nursing care for patients/clients with this condition. Participants will be required to review the educational presentation within 2 weeks. A reminder email will be sent at the end of the 1st and 2nd weeks of access, to remind participants to review the educational presentation. The control group will receive access to the educational intervention once follow up assessments have been completed by both groups.

This study aims to evaluate the effectiveness and app usability of a smartphone app (Oto) in tinnitus management. Oto is a novel multimodal app-delivered approach to tinnitus available for iOS and Android. It combines patient education, cognitive behavioural therapy (CBT), relaxation, mindfulness, and sound therapy in a customisable package. Oto has received Medicines and Healthcare products Regulatory Agency (MRHA) certification as a Class 1 medical device in the UK. This study will test the hypothesis that the use of Oto will significantly reduce tinnitus severity than receiving no tinnitus intervention (i.e., being on a wait list).

This is a two-part study which involves two aims: 1. To develop a consumer- and evidence-informed maternal intrapartum hydration assessment and management intervention protocol for nulliparous women undergoing induction of labour which maintains maternal euvolaemia during parturition. 2. To evaluate the feasibility of undertaking a randomised control trial of the intervention developed in stage one with nulliparous women undergoing induction of labour within the RBWH.

This study aims to evaluate whether an in vitro test enables identification of people with Cystic Fibrosis rare mutations who are clinically responsive to CFTR modulators. Cystic Fibrosis patients with two non-F508del mutations with a positive response in the in vitro testing will undergo cycles of treatment with a triple combination -Elexacaftor/Tezacaftor/Ivacaftor (Trikafta) and matched placebo. Short term improvement in lung function (FEV1) and CF-related symptoms will be used to determine if they respond to the treatment.

This study aims first, to objectively measure co-contraction phenomena during a functionally based repeated grasp and release task in adults with UMN syndrome resulting from a neurological diagnosis. Second, to demonstrate the relationship/impact of abnormal muscle co-contraction on everyday function. Finally, this study aims to objectively measure change in maladaptive co-contraction following OnabotulinumtoxinA injection. This study will contribute to the body of knowledge regarding the pathophysiology of maladaptive muscle co-contraction and explore the impact of co-contraction on everyday function.

MATCH is an eHealth solution, “Music Attuned Technology Care via eHealth,” developed to support carers of people living with dementia to use music intentionally to support care. It is a scalable solution for the growing number of people living with dementia. We developed the ‘MATCH Music Training Program’ as part of this package, which we will trial in a hospital setting in this study.

The REBUILD-SM trial will evaluate the efficacy of a combined self-management package and smartphone application for people with interstitial lung disease (ILD). This intervention will be supported by phone calls from health professionals. Participants will be allocated to either the intervention or control group and take part in the 12-week intervention, with follow-up at 6 and 12 months. It is hoped that the intervention will improve health-related quality of life for people with ILD by helping them better manage their chronic condition.